Who
Gonzalez David Angulo
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Scynexis.
In numbers
- Trades disclosed
- 45
- Buys
- 14
- Sells
- 0
- Bought
- $252K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 4 Jun 2015
- Last trade
- 1 Apr 2026
- Last filed
- 2 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Apr 2026filed 2 Apr 2026 | SCYX ScynexisBiotechnology | SEC FORM 4 Bought | —108,695 | filing |
| 1 Apr 2026filed 2 Apr 2026 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code P | —108,695 | filing |
| 1 Apr 2026filed 2 Apr 2026 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code P | —108,695 | filing |
| 1 Apr 2026filed 2 Apr 2026 | SCYX ScynexisBiotechnology | SEC FORM 4 Bought | —108,695 | filing |
| 29 Jan 2026filed 2 Feb 2026 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —391,333 at $0.00 | filing |
| 29 Jan 2026filed 2 Feb 2026 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —391,333 at $0.00 | filing |
| 17 Oct 2025filed 21 Oct 2025 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | $25K32,500 at $0.76 | filing |
| 9 Apr 2025filed 10 Apr 2025 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | $19K23,000 at $0.84 | filing |
| 20 Mar 2025filed 20 Mar 2025 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | $14K13,800 at $1.05 | filing |
| 19 Mar 2025filed 20 Mar 2025 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | $5,3505,000 at $1.07 | filing |
| 23 Jan 2025filed 27 Jan 2025 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —394,391 at $0.00 | filing |
| 23 Jan 2025filed 27 Jan 2025 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —262,927 at $0.00 | filing |
| 12 Sep 2024filed 16 Sep 2024 | SCYX ScynexisBiotechnology | SEC FORM 4 Bought | $27K20,000 at $1.37 | filing |
| 26 Jan 2024filed 30 Jan 2024 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —431,030 at $0.00 | filing |
| 26 Jan 2024filed 30 Jan 2024 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —290,590 at $0.00 | filing |
| 1 Jan 2023filed 3 Jan 2023 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —165,000 at $0.00 | filing |
| 1 Jan 2023filed 3 Jan 2023 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 4 Feb 2022filed 8 Feb 2022 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —85,000 at $0.00 | filing |
| 4 Feb 2022filed 8 Feb 2022 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —51,100 at $0.00 | filing |
| 29 Jan 2021filed 2 Feb 2021 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
News
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)SCYX · manilatimes.net · 6 Oct 2026
0 headlines in the last 90 days name Gonzalez David Angulo; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.